BeOne Medicines And 2 Stocks That May Be Undervalued By The Market
Name
Current Price
Fair Value (Est)
Discount (Est)
Verra Mobility (VRRM)
$24.37
$47.84
49.1%
Valley National Bancorp (VLY)
$8.90
$17.36
48.7%
TXO Partners (TXO)
$15.08
$29.95
49.7%
Mid Penn Bancorp (MPB)
$26.53
$52.26
49.2%
Lyft (LYFT)
$15.53
$30.54
49.1%
Horizon Bancorp (HBNC)
$14.83
$29.11
49.1%
Expand Energy (EXE)
$117.35
$233.70
49.8%
Central Pacific Financial (CPF)
$26.72
$51.99
48.6%
Brookline Bancorp (BRKL)
$10.43
$20.74
49.7%
Berkshire Hills Bancorp (BHLB)
$25.04
$49.25
49.2%
Click here to see the full list of 163 stocks from our Undervalued US Stocks Based On Cash Flows screener.
We'll examine a selection from our screener results.
Overview: BeOne Medicines Ltd. is an oncology company focused on discovering and developing cancer treatments globally, with a market cap of $32.59 billion.
Operations: The company's revenue is primarily generated from its pharmaceutical products, amounting to $4.18 billion.
Estimated Discount To Fair Value: 47.2%
BeOne Medicines is trading at 47.2% below its estimated fair value, indicating a potential undervaluation based on cash flows. The company has a robust pipeline, including investigational medicines for breast cancer and the approved drug BRUKINSA®, which contributes to its hematology franchise. Recent strategic moves, such as redomiciliation to Switzerland and expanding manufacturing capabilities with an $800 million facility in New Jersey, bolster BeOne's growth strategy and operational resilience.
Our expertly prepared growth report on BeOne Medicines implies its future financial outlook may be stronger than recent results.
Take a closer look at BeOne Medicines' balance sheet health here in our report.
Overview: Elastic N.V. is a search AI company providing hosted and managed solutions for hybrid, public, private, and multi-cloud environments globally, with a market cap of $9.12 billion.
Operations: Elastic generates its revenue primarily from its Software & Programming segment, which amounted to $1.48 billion.
Estimated Discount To Fair Value: 33.9%
Elastic is trading at 33.9% below its estimated fair value, highlighting potential undervaluation based on cash flows. The company anticipates revenue growth of 11.5% annually, outpacing the broader US market. Despite recent insider selling and a current net loss of US$108.11 million for the year, Elastic's strategic collaboration with AWS aims to enhance AI capabilities and drive innovation, potentially supporting future profitability and operational scalability.
Our earnings growth report unveils the potential for significant increases in Elastic's future results.
Click here and access our complete balance sheet health report to understand the dynamics of Elastic.
Overview: Truist Financial Corporation is a financial services company offering banking and trust services in the Southeastern and Mid-Atlantic United States, with a market cap of approximately $53.25 billion.
Operations: Truist Financial's revenue is primarily derived from its Consumer and Small Business Banking segment at $11.04 billion and Wholesale Banking segment at $10.12 billion, while the Treasury & Corporate segment reported a negative contribution of -$9.62 billion.
Estimated Discount To Fair Value: 36.4%
Truist Financial is trading over 20% below its estimated fair value, suggesting potential undervaluation based on cash flows. Despite a dividend yield of 5.12% that may not be fully covered by earnings, the company anticipates revenue growth of 15.2% annually, surpassing the US market average. Recent strategic moves include a $1.25 billion fixed-income offering and innovative payment solutions enhancing cash flow management and operational efficiency for clients, strengthening its financial position amidst board changes and technological advancements.
According our earnings growth report, there's an indication that Truist Financial might be ready to expand.
Delve into the full analysis health report here for a deeper understanding of Truist Financial.
Unlock more gems! Our Undervalued US Stocks Based On Cash Flows screener has unearthed 160 more companies for you to explore.Click here to unveil our expertly curated list of 163 Undervalued US Stocks Based On Cash Flows.
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ONC ESTC and TFC.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 hours ago
- The Hill
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month's supply of Novo Nordisk's semaglutide pen products for $499 through GoodRx. The list price for a monthly supply of a product like Ozempic is normally around $1,000 or more without insurance. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' GoodRx CEO and President Wendy Barnes said in a statement. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them,' added Barnes. 'It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' This is the most recent in similar moves Novo Nordisk has made to make its popular diabetes and weight loss medication more widely available. Earlier this year, the company announced a direct-to-patient program called NovoCare® Pharmacy for uninsured and underinsured individuals who can pay $499 a month for Wegovy. Novo Nordisk also partnered with online telehealth companies like Ro and LifeMD to sell its pens at the same price point. The telehealth company Hims & Hers was also originally included in the partnership, but Novo Nordisk ended it after accusing the company of illegally selling compounded versions of semaglutide. Hims & Hers maintains it is providing personalized, compounded products within regulatory guidelines. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' Dave Moore, executive vice president of U.S. operations of Novo Nordisk, said in a statement. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic® self-pay offer for type 2 diabetes patients at an unprecedented price.' Sen. Bernie Sanders (I-Vt.), a prominent critic of high drug costs, called the announcement a 'modest step forward.' 'Novo Nordisk's move to cut the price of Ozempic to $499 for the uninsured is a modest step forward, but let's not forget,' Sanders said on the social media platform X. 'Ozempic costs just $59 in Germany while it costs less than $5 to make. The U.S. must no longer pay the highest prices in the world for prescription drugs.
Business Wire
2 hours ago
- Business Wire
Levi Strauss & Co. Appoints Chris Callieri as Chief Supply Chain Officer
SAN FRANCISCO--(BUSINESS WIRE)--Levi Strauss & Co. (LS&Co., NYSE: LEVI) today announced the appointment of Chris Callieri as senior vice president and chief supply chain officer, effective September 15. Reporting to Michelle Gass, president and chief executive officer, Callieri will join the company's executive leadership team and will be responsible for the global supply chain operations for the Levi's® brand. His responsibilities include product development, sourcing, global supply management, sustainability, and distribution and logistics. 'We're excited to welcome Chris to LS&Co. at this pivotal moment in our evolution into a DTC-first denim lifestyle company," said Gass. "With a proven track record of delivering results at scale, he's the right leader to strengthen our end-to-end supply chain agility, drive innovation, and advance our sustainability goals — all while delivering exceptional value to our fans worldwide. " Callieri brings more than 20 years of international supply chain experience in the retail and consumer goods industries. He joins LS&Co. from Victoria's Secret & Co., where he served as chief supply chain officer, leading a global team across multiple geographies and overseeing product development, sourcing, production, and distribution and logistics for various categories including intimates, apparel, accessories and beauty. Previously he was at Tory Burch, where he was pivotal in implementing systems like PLM, Merchandise Planning and SAP, and led the transformation of the supply chain. Chris has a long-standing commitment to sustainability and established Tory Burch's sustainability team and strategy. Prior to Tory Burch, Callieri held senior roles at Adidas, including senior vice president, product operations, where he was responsible for materials development, product development, sourcing and logistics for Adidas Lifestyle Brands. Callieri's extensive experience also includes leadership roles at HRC Advisory and A.T. Kearney, where he led various transformation initiatives and developed strategies to improve supply chain responsiveness and product innovation for leading retailers. 'I'm thrilled to join LS&Co. at such an exciting time for the iconic Levi's® brand, a true category leader that thrives at the center of culture," Callieri said. "I look forward to working with the talented LS&Co. team to deliver strong performance, serve our fans around the world, and strengthen Levi's® position as the world's definitive denim lifestyle brand." About Levi Strauss & Co. Levi Strauss & Co. (LS&Co.) is one of the world's largest brand-name apparel companies and a global leader in jeanswear. The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's®, Levi Strauss Signature™ and Beyond Yoga® brands. Its products are sold in approximately 120 countries worldwide through a combination of chain retailers, department stores, online sites, and a global footprint of approximately 3,400 retail stores and shop-in-shops. Levi Strauss & Co.'s reported 2024 net revenues were $6.4 billion. For more information, go to and for financial news and announcements go to
Yahoo
3 hours ago
- Yahoo
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
